Last Updated: September 23, 2026
Welcome, and thank you for your interest in Lighthouse Spouse ("Community Owner," "we," or "us") and our online community, along with any mobile or other downloadable applications that we make available to enable access to the same (collectively, the "Community"). These Terms of Service are a legally binding contract between you and Community Owner regarding your use of the Community.
PLEASE READ THE FOLLOWING TERMS CAREFULLY.
BY ACCEPTING THESE TERMS, EITHER BY CLICKING "I ACCEPT," OR BY OTHERWISE ACCESSING OR USING THE COMMUNITY, YOU AGREE THAT YOU HAVE READ AND UNDERSTOOD, AND, AS A CONDITION TO YOUR USE OF AND ACCESS TO THE COMMUNITY, YOU AGREE TO BE BOUND BY, THE FOLLOWING TERMS AND CONDITIONS, INCLUDING COMMUNITY OWNER'S PRIVACY POLICY (COLLECTIVELY, THESE "TERMS") AND THE ADDITIONAL COMMUNITY TERMS ATTACHED AS EXHIBIT A (THE "ADDITIONAL TERMS") EITHER (A) ON BEHALF OF YOURSELF AS AN INDIVIDUAL, OR (B) IF YOU ARE ACCESSING THE COMMUNITY ON BEHALF OF AN ENTITY, ORGANIZATION, OR COMMUNITY OWNER, ON BEHALF OF SUCH ENTITY, ORGANIZATION OR COMMUNITY OWNER FOR WHICH YOU ACT, AND YOU REPRESENT THAT YOU HAVE THE AUTHORITY TO BIND SUCH ENTITY, ORGANIZATION OR COMMUNITY OWNER TO THIS AGREEMENT. IF YOU ARE NOT ELIGIBLE, OR DO NOT AGREE TO THE TERMS, THEN YOU DO NOT HAVE OUR PERMISSION TO USE THE COMMUNITY. YOUR USE OF THE COMMUNITY, AND COMMUNITY OWNER'S PROVISION OF THE COMMUNITY TO YOU, CONSTITUTES AN AGREEMENT BY COMMUNITY OWNER AND BY YOU TO BE BOUND BY THESE TERMS.
ARBITRATION NOTICE. Except for certain kinds of disputes described in Section 15 (Dispute Resolution and Arbitration), you agree that disputes arising under these Terms will be resolved by binding, individual arbitration, and BY ACCEPTING THESE TERMS, YOU AND COMMUNITY OWNER ARE EACH WAIVING THE RIGHT TO A TRIAL BY JURY OR TO PARTICIPATE IN ANY CLASS ACTION OR REPRESENTATIVE PROCEEDING.
# EXHIBIT A — ADDITIONAL PARTNER TERMS**Applies only to accounts enrolled as an Affiliate, Referral Partner, Seat Licensee, Grey-Label Partner, White-Label Partner, Practitioner, Clergy, or Company Representative.** An End User accepting the EULA solely to use Lighthouse Spouse services does not become a Partner under this Exhibit.These Additional Partner Terms ("Exhibit A") are between Lighthouse Spouse LLC, a Texas limited liability company ("Company"), and the individual or organization identified as the partner in the enrollment screen ("Partner"). For an organization, the person selecting Accept represents that they have authority to bind it. "Party" means either of them and "Parties" means both. The effective date is the time of acceptance recorded by the Company, unless a later date is expressly shown in the Enrollment Summary.The Enrollment Summary is the set of Partner-specific terms displayed to the Partner before acceptance, including the selected model or models, Partner identity, effective date, term, territory, authorized jurisdictions, applicable fees and compensation, seat allocation, applicable branding, and notice contacts. The Company must make that summary available for review and retain it with the accepted version of this Exhibit A. An unfilled commercial term is not supplied by acceptance; a model needing that term does not activate until the Parties agree to it in a retained written or electronic record.By selecting the EULA's Accept button, the Partner accepts the EULA, this Exhibit A, the Enrollment Summary, and the schedules below as one electronic agreement. No handwritten signature, witness, notary, or second Company signature is required by this Exhibit. The Company accepts by enabling the Partner enrollment. Each End User separately accepts the applicable End-User Terms and Informed Consent; the Partner cannot accept for an End User.**Background.** The Company operates an online relationship-support, education, coaching, and referral platform, including faith-integrated content and services. The Partner seeks to participate only in the model or roles identified in the Enrollment Summary. The Parties agree to the following terms.**1. DEFINITIONS** **1.1 "Affiliate"** means a Partner engaged primarily in marketing and audience-driven introductions, compensated as stated in the Enrollment Summary. **1.2 "AACC Code"** means the Code of Ethics of the American Association of Christian Counselors, as amended, adopted voluntarily by the Company as an ethical baseline. **1.3 "Apparent Authority"** means authority that a third party reasonably believes an agent possesses based on the Company's manifestations, as further described in Section 2.2 and Schedule 3. **1.4 "Brand Standards"** means Schedule 2, as amended by the Company from time to time on thirty (30) days' notice. **1.5 "Clinical Services"** means services constituting the practice of psychology, counseling, marriage and family therapy, social work, chemical dependency counseling, or any other licensed behavioral health profession under the laws of the relevant jurisdiction. **1.6 "Clergy"** means an individual who is ordained, commissioned, licensed, or otherwise recognized as a religious leader by a bona fide religious body, and who provides Pastoral Services. **1.7 "Company Marks"** means the name "Lighthouse Spouse," its logos, taglines, trade dress, domain names, and any other indicia designated by the Company. **1.8 "Confidential Information"** means non-public information disclosed by one Party to the other, including business methods, pricing, curricula, client lists, tracking data, and technical systems. It excludes information that is publicly available without breach, independently developed without use of Confidential Information, or rightfully received from a third party without duty of confidentiality. **1.9 "End User"** means an individual who accesses the Platform and accepts the applicable End-User Terms and Informed Consent. **1.10 "Grey-Label"** means a co-branded delivery model in which the Partner's brand appears with the Company Marks, as further described in the Enrollment Summary and Section 7. **1.11 "Pass-Through Referral"** means a referral model in which the Partner receives limited, aggregate reporting and tiered compensation, as described in Sections 5.4 and 5.8. **1.12 "Pastoral Services"** mean non-clinical spiritual care, discipleship, and religious counsel delivered within a faith framework, and explicitly not Clinical Services. **1.13 "Personal Data"** means information relating to an identified or identifiable individual, and includes "protected health information" as defined at 45 C.F.R. § 160.103 where applicable. **1.14 "Practitioner"** means an individual engaged by the Company to deliver services, whether Clinical Services, coaching, education, or consulting. **1.15 "Representative"** means an individual identified in the Enrollment Summary or subsequently authorized by the Company in a written or electronic record under Schedule 3 to act for the Partner or the Company within a defined scope. **1.16 "Seat"** means a single redeemable access right within a Seat License block. **1.17 "Seat License"** means a model in which the Partner purchases a block of Seats for distribution within a defined population. **1.18 "Standard Referral"** means a referral model in which the Partner receives compensation for qualified introductions without ongoing reporting, as described in Section 4. **1.19 "White-Label"** means a delivery model in which services are presented solely under the Partner's brand, as described in Section 8. **2. ENGAGEMENT AND SCOPE** **2.1 Engagement.** The Company engages the Partner, and the Partner accepts engagement, solely for the model(s) shown in the Enrollment Summary at acceptance. No other model is authorized. The Partner's role is limited to that designation. **2.2 Nature of Relationship.** The Partner is an independent contractor. Nothing in this Exhibit A creates a partnership, joint venture, agency (except as expressly limited in Section 5), employment, franchise, or fiduciary relationship. The Parties do not intend to create a franchise. The Partner has no authority to bind the Company except as expressly granted under Section 5 or in a Company-approved written or electronic authorization under Schedule 3. **2.3 No Exclusivity.** Unless the Enrollment Summary states otherwise, the engagement is non-exclusive. **2.4 Territory.** The Partner's activities are limited to the territory stated in the Enrollment Summary. Online activities are limited to the jurisdictions the Partner is authorized to address. Where Clinical Services are involved, the governing jurisdiction is the End User's physical location at the time of service. **2.5 Scope Boundaries.** The Partner shall not: (a) hold itself out as the Company, as licensed by the Company, or as authorized to speak for the Company beyond Schedule 3; (b) provide Clinical Services unless separately licensed and separately engaged under Section 9; (c) provide Pastoral Services outside the Partner's religious authorization; (d) provide legal, medical, or financial advice; (e) make representations regarding outcomes, licensure, accreditation, or regulatory status. **3. CLASSIFICATION AND INDEPENDENT CONTRACTOR STATUS** **3.1** The Partner is an independent contractor for all purposes, including tax, benefits, and tort liability. The Partner is responsible for its own taxes, withholdings, insurance, and business expenses. **3.2** The Partner shall not be eligible for Company employee benefits and shall not hold itself out as an employee. **3.3** The Company does not control the means and methods of the Partner's business operations. To the extent the Company imposes Brand Standards, quality controls, and scope limits, those are imposed to protect the Company's marks, End Users, and legal compliance, and are not intended to create an employment relationship. **3.4** The Partner is free to work for others, subject to Sections 10 (Confidentiality) and 13 (Intellectual Property). **3.5** Each Party is responsible for complying with applicable worker classification rules, including any state ABC test or similar standard applicable to the Partner's location. **3.6 Indemnity for Reclassification.** The Partner shall indemnify the Company against any tax, penalty, or liability arising from a determination that the Partner is an employee, to the extent the determination results from the Partner's conduct or representations. **4. MODEL 1 — STANDARD REFERRAL TERMS** **4.1 Grant.** The Company grants the Partner a non-exclusive, non-transferable, revocable right to refer prospective End Users to the Platform and to use the Company Marks solely as permitted by Schedule 2. **4.2 Authority.** The Partner's authority is limited to making introductions. The Partner has no actual authority to bind the Company, quote pricing, promise outcomes, or negotiate terms. **4.3 Compensation.** The Partner shall be compensated at the rate stated in the Enrollment Summary. Unless the Enrollment Summary states otherwise, compensation is based on collected net revenue (gross receipts less refunds, chargebacks, and taxes) attributable to the Partner's tracked referrals, paid monthly, net 30, subject to a 45-day clawback window for refunds and chargebacks. No percentage is implied if none is stated. **4.4 Tracking.** Referrals are tracked by unique link or code. The attribution window is stated in the Enrollment Summary (default: 90 days). **4.5 Disclosure.** The Partner must conspicuously disclose its affiliate relationship on all promotional materials, in compliance with the FTC Endorsement Guides, 16 C.F.R. Part 255. Required language: "This content contains affiliate links. We may earn a commission if you sign up. Lighthouse Spouse is not a licensed medical provider, and no clinical outcome is promised." **4.6 Prohibited Conduct.** The Partner shall not: (a) bid on Company Marks in paid search without written approval; (b) send unsolicited commercial email in violation of CAN-SPAM; (c) make telemarketing calls in violation of the TCPA or TSR; (d) engage in incentivized or self-referral traffic; (e) use coupon, rebate, or cashback sites without written approval; (f) make claims of clinical efficacy. **4.7 Payment Conditions.** No compensation is payable on fraudulent, self-generated, incentivized, or refunded transactions. The Company may withhold compensation pending investigation of suspicious activity. **5. MODEL 2 — PASS-THROUGH REFERRAL TERMS** **5.1 Grant.** The Company grants the Partner a non-exclusive, non-transferable, revocable right to refer prospective End Users and to receive limited aggregate reporting as described in Section 5.4. **5.2 Limited Administrative Authority.** The Partner is granted limited authority solely to: (a) distribute tracking identifiers; (b) receive aggregate reports; (c) communicate with referred individuals regarding administrative matters (scheduling logistics, access questions) using Company-approved scripts; and (d) escalate issues to the Company. This authority is administrative only and does not extend to pricing, clinical matters, or contracting. **5.3 Compensation.** Compensation is specified in the Enrollment Summary and may comprise: (a) a base referral fee; (b) a retention or utilization bonus; and (c) where applicable, Seat overage participation. A component applies only when its rate or amount and conditions are stated. **5.4 Reporting Limits.** The Partner shall receive only aggregate, de-identified reporting. Permitted and prohibited fields are enumerated in Section 5.4 and the applicable data-processing terms. The Partner shall not attempt to re-identify individuals and shall not request individual-level data except as required by law and approved in writing by the Company. **5.5 Data Protection.** Where the Partner processes Personal Data in connection with this Exhibit A, the Parties shall execute a Data Processing Agreement. The Partner shall implement reasonable administrative, technical, and physical safeguards, including encryption in transit and at rest, access controls, and incident response. **5.6 Notices to Referred Individuals.** The Partner shall provide referred individuals with a written notice, in a form approved by the Company, stating: (a) that the Partner may receive compensation; (b) that services are provided by Lighthouse Spouse; (c) that the Partner has no authority over service delivery or clinical matters; and (d) how to contact the Company directly. **5.7 Crisis Routing.** The Partner shall immediately route any communication indicating suicidal ideation, homicidal ideation, abuse, or medical emergency to emergency services and to the Company's designated crisis contact. The Partner shall not attempt crisis intervention. **5.8 Attribution.** Attribution rules and windows are set out in the Enrollment Summary. The Partner must report an attribution dispute to the Company within thirty (30) days after the applicable statement; the Parties will review tracking records in good faith. **6. MODEL 3 — SEAT LICENSE TERMS** **6.1 Grant of Seat License.** Subject to payment of the fees in the Enrollment Summary, the Company grants the Partner a limited, non-exclusive, non-transferable license to distribute a defined number of Seat redemption codes to individuals within the defined Licensed Population during the License Term. **6.2 License Restrictions.** The Partner shall not: (a) distribute Seats outside the Licensed Population; (b) resell, sublicense, or publicly post Seat codes; (c) alter or obscure Seat redemption mechanics; (d) represent Seats as redeemable for clinical services beyond what the Platform provides; (e) use Seats as a sweepstakes, raffle, or lottery prize without written approval. **6.3 Seat Administration.** The Partner shall designate one or more Seat Administrators. The Administrator shall: (a) maintain a roster of authorized recipients; (b) distribute codes; (c) serve as first-line administrative support; (d) not access clinical records; (e) promptly report suspected leakage. **6.4 End-User Assent.** Each End User must independently accept the End-User Terms of Service & Informed Consent Agreement. The Partner's acceptance does not substitute for End-User assent. The Company may refuse redemption where assent is not captured. **6.5 Utilization Floor, Overage, and Carryover.** Unless the Enrollment Summary states otherwise: (a) utilization floor is 60% of the Seat block per term; (b) authorized redemptions above the block are billed at the overage rate stated in the Enrollment Summary, net 15; (c) unused Seats carry over for one renewal term, capped at 15% of the original block. No overage is authorized without an agreed overage rate. **6.6 Leakage.** Seat leakage is a material breach. Remedies include revocation, reclamation without refund, suspension, and termination for cause. **6.7 Reporting.** The Company shall provide the Partner with aggregated utilization reports monthly. Individual-level reporting requires a lawful basis, End-User consent where required, and written approval. **6.8 Seat Ledger.** The Company shall maintain a Seat Ledger recording all issuances, redemptions, revocations, and reclamations for four (4) years after the License Term. **6.9 No Clinical Direction.** The Partner shall not direct, influence, or attempt to influence the clinical care of any End User, and shall not request clinical information about any End User. **7. MODEL 4 — GREY-LABEL TERMS** **7.1 Grant.** The Company grants the Partner a limited, non-exclusive, non-transferable license to present the Platform in co-branded form, using the Partner's brand together with the Company Marks in the approved lockup described in Schedule 2. **7.2 Shared Presentation, Company-Controlled Delivery.** The Partner controls only the front-end presentation expressly approved by the Company. The Company retains sole control over service delivery, clinical protocol, pricing (except as agreed), data handling, and Platform operation. **7.3 Claims Approval.** All Partner marketing, scripts, landing pages, FAQ content, and support materials must be submitted to the Company and approved in writing before publication. Approval is versioned and expires twelve (12) months from issuance. Unapproved claims are a material breach. **7.4 End-User Disclosure.** The Partner must display, at or before the point of account creation, a conspicuous disclosure approved by the Company stating the division of responsibility, including that clinical services (if any) are provided by licensed professionals engaged by the Company, that the Company is the provider of record, and that the Partner is not a provider of clinical services. **7.5 Consent Chain.** The End User must give informed consent directly. The Partner may not consent on the End User's behalf. **7.6 Quality Controls.** The Partner shall comply with Schedule 2, including monthly compliance attestation, quarterly claims audit, quarterly service-quality review, 24-hour incident reporting, and reasonable access for secret-shopper testing. **7.7 Insurance.** The Partner shall maintain, at its own expense: (a) commercial general liability of not less than $2,000,000 per occurrence; (b) professional liability / errors and omissions of not less than $2,000,000 per claim; (c) cyber liability / network security of not less than $1,000,000 per claim; and (d) workers' compensation as required by law. Certificates of insurance naming the Company as an additional insured (where applicable) must be provided before launch and on renewal. **7.8 Brand Integrity.** The Partner shall not alter Company Marks, combine them with third-party marks without approval, or use them in a manner that disparages or dilutes them. All goodwill inures to the Company. **7.9 Termination of Co-Branding.** On termination, the Partner shall cease all use of Company Marks within fifteen (15) days and shall comply with the transition obligations in Section 16.5 and Schedule 2. **8. MODEL 5 — WHITE-LABEL TERMS** **8.1 Grant.** The Company grants the Partner a limited, non-exclusive, non-transferable license to offer the Platform to End Users under the Partner's own brand, without visible Company Marks, subject to the conditions of this Section 8. **8.2 Conditions Precedent.** The white-label license does not activate until: (a) the Parties execute a Master Services Agreement and Data Processing Agreement; (b) the Partner provides evidence of insurance under Section 8.7; (c) the Company approves the Partner's end-user terms as compliant with Section 8.3; (d) the Partner designates a Compliance Owner; (e) all Partner support staff complete Company training; and (f) the CEO of the Company provides written sign-off. **8.3 End-User Terms Mirror.** The Partner shall present end users with an agreement that incorporates, at minimum: (a) scope limitations, including that services are not a substitute for emergency care; (b) crisis protocol and emergency routing; (c) the informed-consent elements in the applicable End-User Terms and Informed Consent; (d) disclaimers of warranty; (e) limitation of liability; (f) arbitration and class-action waiver, or the substantive equivalent; and (g) a description of the actual provider of services. The Company may require verbatim incorporation or approved reference. **8.4 Actual Provider Disclosure.** The Partner shall clearly identify the actual provider of services to End Users in a manner that satisfies applicable law, including any obligation to identify the licensed professional delivering clinical care and the jurisdiction in which the professional is authorized. **8.5 Partner Authority.** The Partner is the front-facing provider to the End User. The Partner shall not, however: (a) modify clinical protocol; (b) make clinical claims the Company has not approved; (c) represent that it is licensed to provide Clinical Services unless it independently is; (d) bind the Company to any obligation not expressly stated in the Master Services Agreement. **8.6 Quality Controls.** The Partner shall comply with Schedule 2 in full, including monthly attestation, quarterly claims audits, quarterly service-quality reviews, 24-hour incident reporting, annual security review, and brand-integrity audits. The Company retains immediate suspension and kill-switch rights under Sections 8.10 and 16.3. **8.7 Insurance.** The Partner shall maintain, at its own expense: (a) commercial general liability of not less than $3,000,000 per occurrence; (b) professional liability / errors and omissions of not less than $3,000,000 per claim; (c) cyber liability / network security of not less than $2,000,000 per claim; (d) umbrella coverage as reasonably required; and (e) workers' compensation. The Company shall be named as an additional insured on the general liability and, where available, the professional liability policy. Certificates and endorsements are due before activation and annually. **8.8 Indemnity Enhancement.** For white-label deployments, the Partner's indemnity under Section 17 is expanded to cover all claims arising from Partner marketing, Partner representations, Partner support interactions, Partner data handling, and Partner failure to obtain required consents. **8.9 Audit Rights.** The Company may audit the Partner's compliance with this Section 8 upon reasonable notice, or without notice where the Company reasonably suspects a safety, privacy, or regulatory violation. **8.10 Suspension and Termination.** The Company may suspend immediately under Sections 8.10 and 16.3. Termination for cause requires no cure period where the breach involves safety, illegality, or misrepresentation. **8.11 Transition.** On termination, the Partner shall: (a) notify affected End Users within ten (10) business days identifying the change in provider; (b) maintain access for not less than thirty (30) days or provide a documented referral path; (c) return or destroy Company data per the Data Processing Agreement; (d) cease all delivery of Company services under the Partner brand; and (e) preserve records as required by law. **8.12 Minimum Commitments.** A White-Label engagement requires the minimum annual commitment and a term of not less than twenty-four (24) months shown in the Enrollment Summary before acceptance. **9. PRACTITIONER, CLERGY, AND PROFESSIONAL TERMS** **9.1 Practitioner Engagement.** Where the Partner or its personnel provide Clinical Services, coaching, or education through the Platform, the following apply: (a) Licensure. The individual must hold and maintain all licenses and credentials required in each jurisdiction where the individual serves End Users. (b) Verification. The Company shall verify licensure through primary sources before activation and at each renewal, and shall record verification in the Company’s onboarding record. (c) Jurisdictional Limits. The individual shall serve only End Users located in jurisdictions where the individual is authorized. The Company shall enforce this through system-level scheduling controls. (d) Scope. The individual shall practice only within the scope of the individual's license, training, and competence, consistent with the AACC Code and the applicable professional code. (e) Supervision. Associates and provisionally licensed practitioners shall be supervised by a qualified supervisor, with supervision documented and hours recorded. (f) Insurance. The individual shall maintain professional liability coverage of not less than $1,000,000 per claim and $3,000,000 aggregate, or such higher amount as required by law or by the applicable Enrollment Summary or separate practitioner engagement. (g) Documentation. The individual shall maintain clinical records in the form and for the period required by law and Company policy. (h) Records Access. The individual shall provide End Users with access to their records as required by law. **9.2 Clergy and Pastoral Services.** (a) Religious Authorization. Clergy must be ordained, commissioned, licensed, or otherwise recognized by a bona fide religious body, and must provide evidence of that recognition. (b) Non-Clinical Boundary. Pastoral Services are not Clinical Services. Clergy shall not diagnose, treat, or hold themselves out as licensed mental health professionals unless separately licensed and separately engaged. (c) Referral Duty. Clergy shall refer to licensed Clinical Services where the presenting issue exceeds pastoral scope, including where there is suicidal ideation, homicidal ideation, abuse, active addiction, or serious mental illness. (d) Pastoral Confidentiality. Clergy shall maintain confidentiality consistent with their religious tradition and applicable law, and shall not disclose confidential communications to the Company except as necessary for safety or as required by law. (e) Privilege. The Parties acknowledge that clergy-penitent privilege may apply to certain communications and shall not be waived by this Exhibit A. (f) Title and Role. Clergy shall use titles accurately and shall not imply clinical licensure. **9.3 AACC Ethical Guardrails.** All Practitioners, Clergy, Affiliates, and Representatives shall comply with the following, which are material terms: (a) Competence. Serve only within the boundaries of education, training, supervised experience, and licensure. (b) Informed Consent. Obtain documented informed consent before service. (c) Multiple Relationships. Avoid multiple relationships that impair professional judgment; disclose unavoidable ones; never engage in romantic, sexual, or exploitative relationships with End Users. This prohibition is absolute and survives termination. (d) Confidentiality and Limits. Maintain confidentiality, subject to legally mandated reporting, danger to self or others, and abuse disclosure. End Users must be informed of these limits in writing. (e) Referral and Collaboration. Refer when the issue exceeds competence or scope, and coordinate care where lawful. (f) Non-Abandonment. Provide transition and referral on termination. (g) Client Autonomy and Values. Respect End-User autonomy, including the right to be referred to a non-faith-integrated provider without penalty or pressure. (h) Technology Competence. Maintain competence in telehealth delivery; verify identity and physical location; secure the channel. (i) Supervision and Consultation. Seek supervision and consultation proportionate to the work. (j) Financial Integrity. Avoid exploitation, improper bartering, and misleading fee representations. **9.4 Mandatory Reporting.** All Practitioners and Clergy shall comply with applicable mandatory reporting laws, including Texas Family Code § 261.101 (child abuse), Texas Human Resources Code § 48.051 (elder abuse), and analogous laws in each jurisdiction where End Users are located. **9.5 Prohibited Conduct.** No Practitioner, Clergy, or Representative shall: (a) provide services while impaired; (b) practice outside scope; (c) abandon an End User without transition; (d) exploit an End User financially, sexually, or emotionally; (e) disclose Confidential Information without authorization; (f) falsify records; (g) bill for services not rendered; (h) engage in any conduct prohibited by the AACC Code or applicable professional code. **9.6 Reporting of Violations.** Any Party who becomes aware of a violation of this Section 9 shall report it to the Company's Compliance Officer within twenty-four (24) hours. **10. CONFIDENTIALITY** **10.1 Obligation.** Each Party shall hold the other's Confidential Information in confidence, use it only to perform this Exhibit A, and protect it with at least reasonable care. **10.2 Exclusions.** Section 1.8 governs exclusions. **10.3 Required Disclosure.** A Party may disclose Confidential Information where required by law, provided it gives prompt notice where lawful and cooperates in seeking protection. **10.4 End-User Information.** End-User information, including clinical information, is the Company's Confidential Information and, where applicable, protected health information. The Partner shall not access, request, retain, or use End-User clinical information except as expressly authorized and lawful. **10.5 Duration.** Confidentiality obligations continue for five (5) years after termination, and indefinitely for trade secrets and End-User clinical information. **10.6 Whistleblower and Immunity Notice.** Nothing in this Exhibit A prohibits a Party from reporting a suspected violation of law to a government agency, or from making disclosures protected by law. Pursuant to the Defend Trade Secrets Act, 18 U.S.C. § 1833(b), an individual shall not be held criminally or civilly liable for disclosing a trade secret in confidence to a government official or attorney solely for the purpose of reporting or investigating a suspected violation of law, or in a sealed court filing. **11. PRIVACY, DATA PROTECTION, AND CLINICAL RECORDS** **11.1 Compliance.** Each Party shall comply with all applicable privacy laws, including, where applicable, HIPAA (45 C.F.R. Parts 160, 162, and 164), the Health Information Technology for Economic and Clinical Health Act, the Texas Medical Records Privacy Act (Tex. Health & Safety Code Chapter 181), the Texas Data Privacy and Security Act (Tex. Bus. & Com. Code Chapter 541), and analogous state laws. **11.2 Business Associate Agreements.** Where the Partner creates, receives, maintains, or transmits protected health information on behalf of the Company, the Parties shall execute a Business Associate Agreement. Where the Company acts as a business associate of the Partner, the Company shall execute a Business Associate Agreement as business associate. **11.3 Data Processing Agreement.** Where the Partner processes Personal Data outside the scope of the Business Associate Agreement, the Parties shall execute a Data Processing Agreement governing purpose limitation, sub-processors, international transfers, security measures, breach notification, and data return or deletion. **11.4 Security.** Each Party shall implement reasonable administrative, technical, and physical safeguards, including: encryption of Personal Data in transit and at rest; unique credentials; multi-factor authentication; least-privilege access; logging; vulnerability management; and a documented incident response plan. **11.5 Breach Notification.** A Party experiencing a breach of security involving Personal Data shall notify the other Party within twenty-four (24) hours of discovery, and shall cooperate in investigation, notification, and remediation. **11.6 Clinical Records.** Clinical records are owned and maintained by the treating licensed professional and the Company as required by law. The Partner shall not have access to clinical records absent lawful authorization and End-User consent. Records shall be retained per applicable law, and, at minimum, seven (7) years from the last date of service, or longer for minors as required by law. **11.7 No Use for Marketing.** Personal Data, including clinical information, shall not be used for marketing, advertising, profiling, or sale, except as permitted by law and with documented consent. **11.8 De-Identification.** The Company may create de-identified or aggregated data for analytics, quality improvement, and product development, in accordance with 45 C.F.R. § 164.514 where HIPAA applies. **12. REPRESENTATIONS AND WARRANTIES** **12.1 Mutual.** Each Party represents that it has full power and authority to enter into this Exhibit A; that execution does not breach any other agreement; and that it will comply with applicable law. **12.2 Partner Representations.** The Partner represents and warrants that: (a) all information provided to the Company is accurate; (b) it holds all licenses and credentials claimed; (c) it has no disqualifying regulatory history undisclosed; (d) it will comply with the AACC Code and applicable professional codes; (e) it will not make unauthorized claims; (f) it will maintain required insurance; (g) it will comply with all privacy laws; (h) it will obtain all required consents; and (i) it will not engage in any conduct that would bring the Company into disrepute. **12.3 Practitioner Representations.** Each Practitioner represents that: (a) the Practitioner's license is active and in good standing; (b) the Practitioner has disclosed all disciplinary actions; (c) the Practitioner maintains required insurance; (d) the Practitioner will practice within scope; and (e) the Practitioner will comply with the AACC Code. **12.4 Company Representations.** The Company represents that it has authority to grant the rights in this Exhibit A; that, to its knowledge, the Platform does not infringe third-party intellectual property; and that it will maintain the Platform in substantial conformity with Schedule 2. **12.5 No Warranty of Outcome.** THE COMPANY MAKES NO WARRANTY, EXPRESS OR IMPLIED, REGARDING ANY CLINICAL, RELATIONAL, FINANCIAL, OR OTHER OUTCOME. THE PARTNER ACKNOWLEDGES THAT NO OUTCOME IS PROMISED OR GUARANTEED. **13. INTELLECTUAL PROPERTY** **13.1 Company Ownership.** The Company owns all right, title, and interest in the Platform, the Company Marks, curricula, content, software, data models, and derivatives. No rights are granted except as expressly stated. **13.2 Partner Marks.** The Partner grants the Company a limited license to use the Partner's marks solely to perform this Exhibit A, for the term of the Agreement. **13.3 License to Partner.** The Company grants the Partner a limited, non-exclusive, non-transferable, revocable license to use the Company Marks solely as permitted by Schedule 2 and the applicable model. **13.4 Feedback.** Any feedback or suggestions provided by the Partner may be used by the Company without restriction or compensation. **13.5 Residuals.** Nothing in this Exhibit A restricts either Party's use of general knowledge, skills, and experience, provided no Confidential Information is disclosed. **13.6 Trademark Goodwill.** All goodwill from the Partner's use of the Company Marks inures to the Company. The Partner shall not register or attempt to register any mark confusingly similar to the Company Marks. **13.7 Trade Secrets.** The Parties' trade secrets are protected under the Texas Uniform Trade Secrets Act (Tex. Civ. Prac. & Rem. Code Chapter 134A) and the Defend Trade Secrets Act (18 U.S.C. § 1836 et seq.). **14. COMPLIANCE WITH LAW** **14.1 General.** Each Party shall comply with all applicable laws, including those governing professional licensure, consumer protection, advertising, privacy, taxation, anti-kickback, and anti-corruption. **14.2 Advertising.** The Partner shall comply with the FTC Act § 5 (15 U.S.C. § 45) and the FTC Endorsement Guides (16 C.F.R. Part 255), including clear and conspicuous disclosure of material connections. **14.3 Communications.** The Partner shall comply with CAN-SPAM (15 U.S.C. § 7701 et seq.), the Telephone Consumer Protection Act (47 U.S.C. § 227), the FTC Telemarketing Sales Rule (16 C.F.R. Part 310), and applicable state laws. **14.4 Anti-Kickback.** Where any referral involves a federally funded healthcare program, the Partner shall comply with the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)) and the Stark Law where applicable. The Parties do not intend this Exhibit A to violate any such law, and compensation is structured to reflect fair market value for services actually rendered. **14.5 Accessibility.** The Partner shall ensure that its digital properties meet at least WCAG 2.2 Level AA and comply with the Americans with Disabilities Act (42 U.S.C. § 12181 et seq.). **14.6 Export and Sanctions.** The Partner shall comply with applicable export control and sanctions laws. **14.7 Anti-Corruption.** The Partner shall comply with the Foreign Corrupt Practices Act and analogous laws. **14.8 Regulatory Notices.** The Partner shall promptly notify the Company of any regulatory inquiry, subpoena, or investigation relating to the Platform or this Exhibit A. **15. INSURANCE** **15.1 Requirements.** Minimum insurance by model is stated in the Enrollment Summary and Sections 7.7, 8.7, and 9.1(f), as applicable. In all cases, the Partner shall maintain commercial general liability, professional liability where applicable, cyber liability where Personal Data is processed, and workers' compensation as required by law. **15.2 Evidence.** Certificates of insurance are due before activation and annually thereafter. The Company may request endorsements, including additional-insured and waiver-of-subrogation endorsements. **15.3 Notice of Cancellation.** The Partner shall provide thirty (30) days' notice of cancellation or material change in coverage. **15.4 Primary and Non-Contributory.** The Partner's coverage shall be primary and non-contributory with respect to the Company's coverage for the Partner's acts. **16. TERM AND TERMINATION** **16.1 Term.** The initial term is stated in the Enrollment Summary (default: twelve (12) months), with automatic renewal for successive twelve (12) month periods unless either Party provides sixty (60) days' written notice of non-renewal. **16.2 Termination for Convenience.** Either Party may terminate for convenience on sixty (60) days' written notice, provided that Seats already redeemed remain active for the then-current term. **16.3 Termination for Cause.** Either Party may terminate immediately upon written notice for: (a) material breach uncured within fifteen (15) days after notice; (b) insolvency, bankruptcy, or assignment for the benefit of creditors; (c) loss of a required license or insurance; (d) unauthorized claims or misrepresentation; (e) loss of license or credential; (f) any conduct that creates a risk to End-User safety or legal compliance. For breaches involving safety, illegality, or misrepresentation, the Company may terminate immediately without a cure period. **16.4 Effect of Termination.** Upon termination: (a) all licenses cease, except as needed for transition; (b) the Partner shall cease use of Company Marks; (c) accrued compensation through the termination date remains payable, subject to clawback; (d) confidentiality and IP obligations survive; (e) End Users receive transition per Section 16.5. **16.5 End-User Transition.** The Company shall provide End Users with notice and continued access for not less than thirty (30) days, or a documented referral path, consistent with the non-abandonment principle. Where clinical records are involved, the Company shall make them available as required by law. **16.6 Survival.** Sections 1, 3, 9.3(c), 10, 11, 12, 13, 15, 16.6, 17, 18, 19, and 20, and the record-retention provisions of Schedule 4, survive termination to the extent applicable. **17. INDEMNIFICATION** **17.1 By the Partner.** The Partner shall indemnify, defend, and hold harmless the Company and its members, managers, officers, employees, and agents from any claim, loss, liability, damage, cost, or expense (including reasonable attorneys' fees) arising from: (a) the Partner's breach of this Exhibit A; (b) the Partner's negligence or willful misconduct; (c) any representation made by the Partner regarding outcomes, licensure, or the Company's services; (d) the Partner's violation of law; (e) the Partner's handling of Personal Data; (f) the Partner's failure to obtain required consents; (g) any claim by the Partner's personnel for employment-related benefits or taxes; and (h) in white-label deployments, any claim arising from the Partner's front-end presentation or support. **17.2 By the Company.** The Company shall indemnify, defend, and hold harmless the Partner from any third-party claim arising from: (a) the Company's breach of this Exhibit A; (b) the Company's gross negligence or willful misconduct in delivering the Platform; and (c) a claim that the Company Marks infringe a third party's intellectual property. **17.3 Procedure.** The indemnified Party shall give prompt notice, permit the indemnifying Party to control the defense, and cooperate reasonably. The indemnifying Party shall not settle in a manner that imposes liability on the indemnified Party without consent. **17.4 Exclusions.** Indemnity does not extend to claims caused by the indemnified Party's own negligence or willful misconduct. **18. LIMITATION OF LIABILITY** **18.1** EXCEPT FOR (A) THE PARTNER'S INDEMNIFICATION OBLIGATIONS, (B) BREACH OF CONFIDENTIALITY, (C) INFRINGEMENT OR MISUSE OF INTELLECTUAL PROPERTY, (D) THE PARTNER'S OBLIGATIONS UNDER SECTION 9 (ETHICAL GUARDRAILS) AND SECTION 14 (COMPLIANCE), AND (E) FRAUD OR WILLFUL MISCONDUCT, NEITHER PARTY SHALL BE LIABLE FOR INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES, OR FOR LOST PROFITS, EVEN IF ADVISED OF THE POSSIBILITY. **18.2** EXCEPT AS PROVIDED IN SECTION 18.1, EACH PARTY'S TOTAL LIABILITY UNDER THIS AGREEMENT SHALL NOT EXCEED THE GREATER OF (A) THE AMOUNTS PAID OR PAYABLE BY THE COMPANY TO THE PARTNER IN THE TWELVE (12) MONTHS PRECEDING THE CLAIM, OR (B) FIFTY THOUSAND DOLLARS ($50,000). FOR WHITE-LABEL ENGAGEMENTS, THE CAP IS THE GREATER OF FEES PAID IN THE PRECEDING TWELVE (12) MONTHS OR TWO HUNDRED FIFTY THOUSAND DOLLARS ($250,000). **18.3** THE PARTIES ACKNOWLEDGE THAT THIS SECTION ALLOCATES RISK AND IS A MATERIAL INDUCEMENT TO ENTER THIS AGREEMENT. **18.4** Nothing in this Section limits liability that cannot be limited under applicable law, including for gross negligence, willful misconduct, or fraud. **19. DISPUTE RESOLUTION** **19.1 Negotiation.** The Parties shall first attempt good-faith negotiation for thirty (30) days after written notice of a dispute. **19.2 Mediation.** If negotiation fails, the Parties shall mediate in Collin County, Texas, before a mutually acceptable mediator, unless the dispute involves injunctive relief or confidentiality. **19.3 Binding Arbitration.** Any dispute not resolved by negotiation or mediation shall be resolved by binding arbitration administered by the American Arbitration Association under its Commercial Arbitration Rules, with the seat of arbitration in Collin County, Texas. The arbitrator shall be a single arbitrator experienced in technology, healthcare, or commercial licensing, as appropriate. The Federal Arbitration Act (9 U.S.C. § 1 et seq.) and the Texas Arbitration Act (Tex. Civ. Prac. & Rem. Code Chapter 171) govern. **19.4 Injunctive Relief.** Either Party may seek injunctive or equitable relief in a court of competent jurisdiction to protect intellectual property, Confidential Information, or End-User safety. **19.5 Fees.** Each Party bears its own fees and costs, and one-half of the arbitration fees, unless the arbitrator determines otherwise. **19.6 Small Claims / Individual Actions.** Nothing prevents either Party from bringing an individual action in small claims court. **19.7 Class Actions.** Disputes shall proceed on an individual basis. Neither Party may bring or participate in a class, collective, or representative action against the other; provided that this subsection does not apply where prohibited by law. **19.8 Confidentiality of Proceedings.** Arbitration proceedings and awards are confidential except as required by law. **20. GENERAL PROVISIONS** **20.1 Governing Law.** This Exhibit A is governed by the laws of the State of Texas, without regard to conflict-of-laws principles, except that mandatory licensure, privacy, and consumer-protection laws of the End User's jurisdiction apply to the extent they cannot be waived. **20.2 Venue.** Subject to Section 19, exclusive venue lies in the state and federal courts located in Collin County, Texas. **20.3 Notices.** Notices must be in writing and delivered to the contact details in the Enrollment Summary, and are effective upon receipt. **20.4 Assignment.** The Partner may not assign this Exhibit A without the Company's written consent. The Company may assign to an affiliate or in connection with a merger or asset sale. **20.5 Entire Agreement.** This Exhibit A, the Enrollment Summary, and the applicable EULA govern the Partner engagement. If they conflict on a Partner-specific matter, this Exhibit A controls unless the Enrollment Summary expressly identifies an override. They supersede prior drafts of these Partner terms. Separately accepted data-processing, business associate, master services, practitioner, or other written agreements remain effective according to their terms. **20.6 Amendment.** Material changes to this Exhibit A or the Enrollment Summary require affirmative electronic acceptance by the Partner or a separate writing agreed by both Parties. The Company may update Schedule 2 on thirty (30) days' notice as stated there. **20.7 Four-Tiered Severability Hierarchy.** If any provision, clause, or term of this Exhibit A is held to be invalid, illegal, or unenforceable by a court or arbitrator of competent jurisdiction, the Parties intend that such provision be severed and reformed through the following four-tiered hierarchy to preserve the economic and legal bargain of the Parties: - Tier 1 (Narrow Reformation & Blue-Penciling): The invalid or unenforceable provision shall first be modified, re-scoped, or "blue-penciled" by the court or arbitrator to the minimum extent necessary to render it valid, legal, and enforceable while closest approximating the original intent of the Parties. * Tier 2 (Substitution of Equivalent Term): If Tier 1 modification is impossible or insufficient, the invalid provision shall be deemed excised and automatically replaced with a valid, enforceable substitute provision that most nearly accomplishes the original economic, legal, and operational objectives of the severed provision. - Tier 3 (Severance of Specific Clause): If Tiers 1 and 2 cannot be applied, the specific offending clause, sentence, or sub-paragraph shall be severed entirely from this Exhibit A, leaving all remaining clauses, sentences, and sub-paragraphs fully intact and operational. * Tier 4 (Severance of Entire Section or Exhibit): If the severance under Tier 3 would fundamentally alter the essential economic or foundational bargain of the Agreement such that enforcement becomes inequitable, the entire affected Section or Exhibit shall be severed, and the remainder of the Agreement shall continue in full force and effect. **20.8 Waiver.** No waiver is effective unless in writing. Failure to enforce is not a waiver. **20.9 Force Majeure.** Neither Party is liable for delay caused by events beyond its reasonable control, provided it gives prompt notice and mitigates. **20.10 Relationship of Parties.** Nothing creates a partnership, joint venture, agency (except as expressly limited), employment, or franchise. **20.11 Electronic Acceptance.** The Partner accepts this Exhibit A by selecting the EULA acceptance button after the Exhibit and Enrollment Summary are made available. The Company accepts by enabling the Partner enrollment. The Company will retain an electronic record of the accepted version, the Enrollment Summary, and the acceptance event. No separate signature block is required. **20.12 Further Assurances.** Each Party shall execute documents reasonably necessary to effectuate this Exhibit A. **20.13 No Third-Party Beneficiaries.** Except for indemnified parties, this Exhibit A creates no third-party beneficiaries. End-User rights, if any, are governed by the End-User Terms and Informed Consent. **20.14 Interpretation.** Headings are for convenience only. "Including" means "including without limitation." **20.15 Attorneys' Fees.** The prevailing Party in any action is entitled to recover reasonable attorneys' fees and costs, subject to Section 19.## SCHEDULE 1 — ENROLLMENT SUMMARY FIELDS AND MODEL RULES**1. Model election.** The enrollment screen must expressly identify each selected model: Standard Referral; Pass-Through Referral; Seat License; Grey-Label; White-Label; Practitioner; Clergy/Pastoral; or Company Representative. A model not selected is not authorized. Practitioner, Clergy, and Representative authority requires the role-specific qualifications and approvals in Sections 9 and Schedule 3.**2. Effective date, term, and territory.** The enrollment screen must state the Partner's legal name and contact information, the selected model or models, territory, and, if Clinical Services are involved, authorized jurisdictions. The initial term is twelve (12) months unless a different term is shown. The engagement renews for successive twelve (12) month terms unless either Party gives sixty (60) days' notice under Section 16. White-Label and Grey-Label engagements have a twenty-four (24) month minimum term if activated under paragraph 5 of this Schedule.**3. Standard and Pass-Through Referral compensation.** The Enrollment Summary must state the applicable base percentage of collected net revenue, any retention bonus amount and measurement date, any volume thresholds and tier rates, and any seat overage participation. If a percentage or payment amount is absent, that compensation component is not agreed and will not accrue until the Parties affirmatively agree on it. The default attribution window is ninety (90) days; the default clawback window is forty-five (45) days; and undisputed earned amounts are paid monthly, net thirty (30). The Enrollment Summary must select first-touch, last-touch, or split attribution before paid referrals activate. Excluded sources are self-referrals, employee referrals, existing customers, and coupon or cashback sites unless the Company expressly approves an exception.**4. Seat License.** Before a Seat License activates, the Enrollment Summary must specify the number of Seats, permitted population, designated Seat Administrator, and applicable per-Seat fee. It may state pricing tiers for 1–99, 100–499, 500–999, and 1,000 or more Seats, but a tier price applies only if the corresponding dollar amount is stated. It must state any overage price before overages are authorized and specify the redemption method (unique code, single sign-on, or invitation). Unless the Enrollment Summary changes them, the utilization floor is sixty percent (60%); unused Seats may carry over for one renewal term up to fifteen percent (15%) of the original block; reports are aggregate only; and the Seat Ledger is retained for four (4) years after the License Term.**5. Branding and operating requirements by model.** Standard Referral, Pass-Through Referral, and Seat License use Company-only branding. Grey-Label uses an approved co-brand with "Powered by Lighthouse Spouse" attribution. White-Label uses the Partner's approved branding and does not display Company Marks to End Users. Each model requires Company approval of claims and applicable End-User disclosures. A Partner Compliance Owner is required for Seat License, Grey-Label, and White-Label and recommended for Pass-Through Referral. Monthly compliance attestation and quarterly claims audit apply to Grey-Label and White-Label. Quarterly quality review applies to Seat License, Grey-Label, and White-Label. An annual security review applies to Pass-Through Referral, Seat License, Grey-Label, and White-Label. Grey-Label and White-Label require CEO written approval before launch.**6. Insurance minimums.** Standard Referral, Pass-Through Referral, and Seat License require $1,000,000 commercial general liability; Pass-Through Referral and Seat License also require $1,000,000 cyber liability. Grey-Label requires $2,000,000 commercial general liability, $2,000,000 professional liability, and $1,000,000 cyber liability. White-Label requires $3,000,000 commercial general liability, $3,000,000 professional liability, and $2,000,000 cyber liability. Sections 7.7, 8.7, and 9.1(f) apply where their coverage is higher or more specific. Workers' compensation applies as required by law.**7. Annual commitments and commercial rates.** The minimum annual commitment for Standard Referral is $0; for Pass-Through Referral, $10,000; for Seat License, $25,000; for Grey-Label, $100,000; and for White-Label, $250,000. A commitment applies only when its amount is displayed for the selected model in the Enrollment Summary before acceptance. Revenue-share rates must be expressly stated in the Enrollment Summary; no rate is established by this Schedule. Seat License is priced per Seat.**8. Notices and special terms.** The Enrollment Summary must provide both Parties' notice email addresses and any required postal addresses. Special terms, if any, apply only when shown before acceptance or separately accepted by both Parties in a retained written or electronic record.## SCHEDULE 2 — BRAND AND DELIVERY STANDARDS (Amendable by the Company on thirty (30) days' notice, subject to Section 20.6.) **S2-1. BRAND USE** 1. Company Marks must be used in the exact form supplied, without alteration, recoloring, or distortion. 2. Minimum clear space equal to the height of the mark's primary element must surround the mark. 3. The mark may not appear on a background that impairs legibility. 4. The mark may not be combined with third-party marks without written approval. 5. The mark may not be used in a manner implying endorsement of a product, candidate, cause, or position. 6. The mark may not be used in proximity to content that is sexually explicit, violent, hateful, or defamatory. 7. Required attribution in grey-label: "Powered by Lighthouse Spouse" in the approved lockup. 8. In white-label deployments, Company Marks must not be exposed to End Users. **S2-2. APPROVED CLAIMS LANGUAGE** Approved: - "Faith-informed relationship support and education, delivered online." - "Connect with licensed professionals and pastoral counselors." - "AACC-informed ethical standards." - "Not a substitute for emergency services or medical care." Prohibited: - "Guaranteed to save your marriage." - "Cures depression, anxiety, or trauma." - "Clinically proven" (absent an approved study). - "Free therapy." - "Licensed in all 50 states" (unless verifiable and current). - Any statement implying licensure, accreditation, or governmental endorsement not documented. **S2-3. DELIVERY STANDARDS**Identity verification is required at intake for clinical and pastoral services. Physical location must be confirmed at each clinical session. Crisis screening is required at intake and at each session. Emergency routing information must display 988, 911, and relevant local resources. Informed consent must be captured before the first service. Clinical sessions must use an encrypted, access-controlled platform. Records must be retained under Section 11.6. On termination, End Users receive notice and a referral or transition path under Section 16.5. Administrative support inquiries must be answered within one business day; clinical or safety concerns must be escalated within four hours. These standards apply to the extent relevant to the Partner's selected role and the Company's service delivery.**S2-4. PROHIBITED DELIVERY PRACTICES** 1. Delivering services from unencrypted consumer channels (e.g., personal email, SMS) for clinical content. 2. Recording sessions without documented consent. 3. Delivering services while impaired. 4. Delivering clinical services across jurisdictional lines without authorization. 5. Permitting unlicensed personnel to perform clinical tasks. 6. Using AI-generated clinical advice without licensed human review and disclosure. 7. Conditioning access on positive reviews, testimonials, or continued purchase. **S2-5. AI AND AUTOMATION** Any automated or AI-assisted feature must: (a) be disclosed to End Users; (b) be reviewed by a licensed professional before deployment; (c) not provide diagnosis or treatment; (d) not be used for crisis response; (e) comply with applicable AI transparency requirements; and (f) be documented in the Company's AI register. **S2-6. ACCESSIBILITY** All digital properties must meet WCAG 2.2 Level AA. Partner-provided front ends must be tested and documented before launch. **S2-7. REVIEW** The Company may amend this Schedule 2 on thirty (30) days' notice. Continued participation after the effective date of an amendment constitutes acceptance of a nonmaterial operational update. A material change requires affirmative acceptance under Section 20.6. ## SCHEDULE 3 — REPRESENTATIVE AUTHORITYA Partner organization must identify the individual accepting these terms and that person's title in the Enrollment Summary. By selecting Accept, that individual represents that they may bind the Partner. Acceptance alone does not authorize the individual to act for the Company.Any additional Partner Representative must be identified in a Company-approved written or electronic authorization specifying name, title, permitted activities (such as administering Seats, receiving aggregate reports, or distributing codes), effective date, and expiration or review date. Execution of additional agreements is permitted only if expressly included in that authorization. Pricing, clinical direction, media statements, receipt of Company funds, and contracting on the Company's behalf are excluded unless expressly and separately authorized in writing by the Company.Nick Denman, as Chief Executive Officer, is designated in the source as the Company Representative authorized to execute agreements, grant model licenses, suspend or terminate for cause, and approve White-Label activation, subject to the Company's governing documents. This Exhibit does not independently confer authority to waive arbitration, assign Company Marks, or sell Company equity.No Representative may promise a clinical, relational, financial, or legal outcome; falsely claim licensure or accreditation; provide clinical advice, diagnosis, or crisis intervention outside an independently licensed and separately engaged role; or alter End-User Terms. Except where separately authorized in a Company-approved record, a Representative may not quote or modify pricing, bind the Company, receive Company funds, speak for the Company to media, or waive the Company's confidentiality rights. This Schedule defines actual delegated authority and does not purport to eliminate apparent authority that may arise under applicable law.## SCHEDULE 4 — ELECTRONIC ACCEPTANCE AND RECORDSThe Company will maintain an electronic acceptance record identifying the version of the EULA and this Exhibit A, the Partner and accepting account, the Enrollment Summary shown at acceptance, the UTC acceptance timestamp, and available technical evidence such as IP address and device details. The Company may keep a document hash and evidence of access to electronic records. It will record model approval, role qualifications, training, insurance, licensure verification, applicable data-processing and business associate agreements, claims approvals, and any CEO sign-off before activating a model that requires them.During the engagement the Company will keep records of required compliance attestations, claims audits, quality and security reviews, insurance and training renewals, license re-verification, Seat issuances and redemptions, and incidents, as applicable to the selected model. Incident records will document the date, type, reporting person, action taken, resolution, and retention period.Subject to any longer period required by applicable law, the Company will retain accepted agreements and authority records for seven (7) years after termination; electronic acceptance logs for seven (7) years; Seat Ledgers for four (4) years after the applicable term; referral attribution logs for a rolling twelve (12) months; consent records for seven (7) years after the last service; incident reports for ten (10) years; and compliance attestations, training certifications, and claims approvals for four (4) years. Clinical record retention is governed by Section 11.6 and applicable law.